| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
The primary targets of 6-O-methylcatalpol are protozoan parasites, including Trypanosoma brucei rhodesiense and Leishmania donovani. In silico docking studies have suggested that Trypanosoma cruzi's Old Yellow Enzyme (OYE) could be a potential molecular target for 6-O-methylcatalpol. The compound's antiprotozoal activity may involve inhibition of key metabolic enzymes in the parasites. Further studies are needed to confirm these predicted targets and elucidate the precise mechanism of action.
|
|---|---|
| ln Vitro |
In vitro studies have demonstrated that 6-O-methylcatalpol exhibits antiprotozoal activity against Trypanosoma b. rhodesiense and Leishmania donovani with IC₅₀ values of 32.5 and 8.3 μg/mL, respectively. This activity suggests that the compound is more potent against Leishmania than against Trypanosoma. The compound has been identified in a methanolic extract of Buddleja globosa leaves with activity against Trypanosoma cruzi. These findings support its potential as an antiprotozoal agent.
|
| ln Vivo |
In vivo antiprotozoal activity of 6-O-methylcatalpol has not been extensively documented in the published literature. Most studies have focused on in vitro characterization of its antiprotozoal effects. The compound has been identified in plant extracts with potential trypanocidal activity. Animal model studies are needed to evaluate whether the in vitro activity translates to in vivo efficacy against protozoan infections. Further preclinical investigations are required to assess its therapeutic potential.
|
| Enzyme Assay |
For evaluation of antiprotozoal activity, standard in vitro assays are employed. Cultured parasites such as Trypanosoma brucei rhodesiense or Leishmania donovani are incubated with serial dilutions of test compound in 96-well microtiter plates. After 48-72 hours, cell viability is assessed using resazurin or Alamar Blue reduction assays. IC₅₀ values are calculated from dose-response curves. Positive controls such as suramin or amphotericin B are included for assay validation. For target identification, enzyme inhibition assays and molecular docking studies can be performed.
|
| Cell Assay |
For in vitro cell-based activity assessment, parasites are cultured in appropriate media. Trypanosoma brucei rhodesiense is cultured in HMI-9 medium supplemented with 10% fetal bovine serum. Leishmania donovani is cultured in M199 medium. Cells are seeded at appropriate densities and treated with various concentrations of 6-O-methylcatalpol. After 48-72 hours of incubation at 37°C, cell viability is measured using fluorometric or colorimetric methods. Cytotoxicity against mammalian cells may also be assessed.
|
| Animal Protocol |
In vivo animal studies for this compound have not been extensively reported. For similar antiprotozoal iridoid glycosides, typical protocols involve mouse models of infection. Mice are infected with Trypanosoma brucei or Leishmania and treated with the test compound via oral or intraperitoneal administration. Parasitemia is monitored, and survival time is recorded. Standard protocols for antiprotozoal efficacy studies are described in the literature and can be adapted for this compound.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 6-O-methylcatalpol have not been comprehensively characterized. As an iridoid glycoside with a molecular weight of 376.36 g/mol, it is expected to be relatively polar and may have limited oral bioavailability. The glycoside moiety may be metabolized by intestinal enzymes. Specific PK parameters such as half-life, clearance, and protein binding have not been reported. Further pharmacokinetic studies are needed to understand its absorption, distribution, metabolism, and excretion.
|
| Toxicity/Toxicokinetics |
Toxicological data for 6-O-methylcatalpol are limited. As a naturally occurring iridoid glycoside from traditional medicinal plants, it may have a favorable safety profile. However, systematic toxicological studies including acute toxicity, genotoxicity, and repeated-dose toxicity have not been published. Cytotoxicity against mammalian cell lines requires further evaluation. Safety assessments are needed before considering therapeutic applications.
|
| References | |
| Additional Infomation |
6-O-methylcatalol has been reported to exist in Oreosolen wattii, Scrophularia ningpoensis, and other organisms with available data.
6-O-Methylcatalpol is a research compound with antiprotozoal activity. It is isolated from Scrophularia ningpoensis roots and used as a reference standard for natural product research. The compound has been studied for its anti-protozoal activity against Trypanosoma and Leishmania species. No clinical trials or regulatory approvals have been reported. Future research may explore its mechanism of action and potential as a lead compound for antiprotozoal drug development. |
| Molecular Formula |
C16H24O10
|
|---|---|
| Exact Mass |
376.136
|
| CAS # |
1617-84-1
|
| PubChem CID |
53248734
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
-2.7
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
26
|
| Complexity |
557
|
| Defined Atom Stereocenter Count |
11
|
| SMILES |
CO[C@H]1[C@@H]2C=CO[C@H]([C@@H]2[C@@]3([C@H]1O3)CO)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O
|
| InChi Key |
CQHVYUDLQLYNAI-GSKJLTDHSA-N
|
| InChi Code |
InChI=1S/C16H24O10/c1-22-12-6-2-3-23-14(8(6)16(5-18)13(12)26-16)25-15-11(21)10(20)9(19)7(4-17)24-15/h2-3,6-15,17-21H,4-5H2,1H3/t6-,7-,8-,9-,10+,11-,12+,13+,14+,15+,16-/m1/s1
|
| Chemical Name |
(2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-[[(1S,2S,4S,5S,6R,10S)-2-(hydroxymethyl)-5-methoxy-3,9-dioxatricyclo[4.4.0.02,4]dec-7-en-10-yl]oxy]oxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
